文献速递静脉血栓栓塞

原始与改良Caprini评分对COVID-19患者静脉血栓栓塞症的预测效能相当

The original and modified Caprini score equally predicts venous thromboembolism in COVID-19 patients.
PubMed 文献 · J Vasc Surg Venous Lymphat Disord · 2021-03-17

该回顾性研究纳入168例2020年4月30日至5月29日住院的COVID-19患者,比较原始Caprini评分(2005版)与包含D-二聚体升高及COVID-19专项赋分的多种改良版本对静脉血栓栓塞症(VTE)的预测能力。结果显示8个版本评分均与住院期间VTE显著相关,出院(死亡)时评估的原始评分预测性最高,提示COVID-19患者可直接使用原始Caprini评分。

要点

  • 8个版本Caprini评分均与住院VTE显著相关,原始版出院时评估预测性最高
  • 住院期间症状性VTE检出11例(6.5%),出院后累积发生率7.1%
  • 49例(29%)接受延长抗血栓治疗,6个月出血累积发生率1.8%

核心结论

  • 原始Caprini评分与含COVID-19专项赋分的各改良版本对COVID-19患者VTE预测效能相当,使用原始评分即合适。

研究设计与样本

  • 回顾性研究,数据来自电子病历并已嵌入Caprini评分,共168例患者(男83例、女85例,年龄58.3±12.7岁)。
  • 评分计算两次:入院时由医生计算,出院(死亡)时由研究者计算,最终评估纳入住院期间出现的额外危险因素。
  • 改良版本在原始2005版基础上增加D-二聚体升高及COVID-19专项赋分:无症状2分、有症状3分、有症状且D-二聚体阳性5分。
  • 主要终点为住院期间经影像或尸检确认的症状性VTE;次要终点包括住院期间及6个月随访事件。

主要发现

  • 原始Caprini评分入院时2–12分(5.4±1.8),出院或死亡时2–15分(5.9±2.5)。
  • 含COVID-19专项5分赋分的改良版本最高分为5–20分(10.0±3.0)。
  • 住院期间检出症状性VTE 11例(6.5%);28例(16.7%)入住ICU,8例(4.8%)需有创机械通气,8例(4.8%)死亡。
  • 临床相关非大出血2例(1.2%);出院后仅报告症状性VTE,累积发生率7.1%,未影响Caprini评分的预测性。
  • 8个版本评分均与住院VTE频率显著相关,出院(死亡)时评估的原始评分预测性最高。

关键数值与推荐

  • 抗凝方案:预防剂量依诺肝素40 mg每日一次占2.4%,中间剂量80 mg每日一次占76.8%,治疗剂量1 mg/kg每日两次占20.8%。
  • 49例(29%)接受延长抗血栓治疗,6个月出血累积发生率1.8%。

临床怎么用

  • COVID-19住院患者可采用原始Caprini评分进行VTE风险评估,无需依赖COVID-19专项赋分改良版本。
  • 出院(死亡)时结合住院期间新增危险因素的评分评估可能提供最高的VTE预测性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The study aimed to validate the original Caprini score and its modifications considering coronavirus disease (COVID-19) as a severe prothrombotic condition in patients admitted to the hospital. METHODS: The relevant data were extracted from the electronic medical records with an implemented Caprini score and were retrospectively evaluated. The score was calculated twice: by the physician on admission and by the investigator at discharge (death). The final assessment considered additional risk factors that occurred during inpatient treatment. Besides the original Caprini score (a version of 2005), the modified version added the elevation of D-dimer and specific scores for COVID-19 as follows: two points for asymptomatic, three points for symptomatic, and five points for symptomatic infection with positive D-dimer. Cases were evaluated retrospectively. The primary end point was symptomatic venous thromboembolism (VTE) detected during inpatient treatment and confirmed by appropriate imaging testing or autopsy. The secondary end points included those observed during hospitalization (admission to the intensive care unit, a requirement for invasive mechanical ventilation, death, bleeding), and those assessed at 6-month follow-up (symptomatic VTE, bleeding, death). The association of eight different versions of the Caprini score with VTE events was evaluated. RESULTS: A total of 168 patients (83 males and 85 females at the age of 58.3 ± 12.7 years) were admitted to the hospital between April 30 and May 29, 2020, and were discharged or died to the time of data analysis. The original Caprini score varied between 2 and 12 (5.4 ± 1.8) at the admission and between 2 and 15 (5.9 ± 2.5) at discharge or death. The maximal score was observed with modification including specific COVID-19 points of 5 to 20 (10.0 ± 3.0). Patients received prophylactic (enoxaparin 40 mg once daily: 2.4%), intermediate (enoxaparin 80 mg once daily: 76.8%), or therapeutic (enoxaparin 1 mg/kg twice daily: 20.8%) anticoagulation. Despite this, symptomatic VTE was detected in 11 (6.5%) inpatients. Of the 168 individuals, 28 (16.7%) admitted to the intensive care unit, 8 (4.8%) required invasive mechanical ventilation, and 8 (4.8%) died. Clinically relevant nonmajor bleeding was detected in two (1.2%) cases. The Caprini score of all eight versions demonstrated a significant association with inpatient VTE frequency. The highest predictability was observed for the original scale when assessed at discharge (death). Only symptomatic VTE was reported after discharge with a cumulative incidence of 7.1%. This did not affect the predictability of the Caprini score. Extended antithrombotic treatment was prescribed to 49 (29%) patients with a cumulative incidence of bleeding of 1.8% at 6 months. CONCLUSIONS: The study identified a significant correlation between the Caprini score and the risk of VTE in patients with COVID-19. All models including specific COVID-19 scores showed equally high predictability, and use of the original Caprini score is appropriate for patients with COVID-19.

来源:J Vasc Surg Venous Lymphat Disord,查看原文。版权归原作者所有。

引用

  1. Tsaplin S, Schastlivtsev I, Zhuravlev S, et al. The original and modified Caprini score equally predicts venous thromboembolism in COVID-19 patients. J Vasc Surg Venous Lymphat Disord. 2021. PMID: 33744497. doi:10.1016/j.jvsv.2021.02.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。